16. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463.

17. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317–326.


Continue Reading

18. Kim YJ, Lee WJ, Woo SM, et al. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. Radiat Oncol. 2013;8:160.

19. Ikeda M, Ioka T, Ito Y, et al. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85(1):163–169.

20. Wang BH, Cao WM, Yu J, Wang XL. Gemcitabine-based concurrent chemo­radiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer. Asian Pac J Cancer Prev. 2012;13(5):2129–2132.

21. Shinchi H, Maemura K, Mataki Y, et al. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci. 2012;19(2):152–158.

22. Sudo K, Yamaguchi T, Ishihara T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;80(1):119–125.

23. Huang J, Robertson JM, et al. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol. 2011;99(2):114–119.

24. Cardenes HR, Moore AM, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresect­able, pancreatic cancer: a Hoosier Oncology Group study. Am J Clin Oncol. 2011;34(5):460–465.

25. Kim HS, Yi SY, Jun HJ, et al. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. Anticancer Drugs. 2010;21(1):107–112.

26. Jackson AS, Jain P, Watkins GR, et al. Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. Clin Oncol (R Coll Radiol). 2010;22(7):570–577.

27. Kim HM, Bang S, Park JY, et al. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009;63(3):535–541.

28. Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pan­creatic cancer: a multicenter phase II trial. J Clin Oncol. 2008;26(6):942–947.

29. Yamazaki H, Nishiyama K, Koizumi M, et al. Concurrent chemoradio­therapy for advanced pancreatic cancer: 1,000 mg/m2 gemcitabine can be administered using limited-field radiotherapy. Strahlenther Onkol. 2007;183(6):301–306.

30. Saif MW, Black G, Roy S, et al. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J. 2007;13(4):247–256.

31. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):801–808.

32. Magnino A, Gatti M, Massucco P, et al. Phase II trial of primary radia­tion therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. Oncology. 2005;68(4–6):493–499.

33. Okusaka T, Ito Y, Ueno H, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer. 2004;91(4):673–677.

34. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003;34(2–3):107–116.

35. Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with local­ized, unresectable pancreatic cancer. J Surg Oncol. 2002;81(3):138–143.

36. National Comprehensive Cancer Network [webpage on the Internet]. Clinical practice guidelines in oncology (NCCN guidelines) pancreatic adenocarcinoma, version 2. Fort Washington, PA: National Compre­hensive Cancer Network; 2014. Available from: http://www.nccn.org/professionals/physiciangls/fguidelines.asp#pancreatic. Accessed October 10, 2014.

37. Tada M, Arizumi T, Nakai Y, et al. Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy. Chemotherapy. 2008;54(4):302–308.

38. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999;28(1):1–9.

39. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.

SUPPLEMENTARY MATERIAL

(To view a larger version of Table S1, click here.)

Source: OncoTargets and Therapy
Originally published November 9, 2015.